Chemotherapy-induced pulmonary hypertension: Role of alkylating agents

Frederic Perros (le Plessis-Robinson, France), Benoit Ranchoux, Sven Günther, Rozenn Quarck, Marie-Camille Chaumais, Peter Dorfmüller, Fabrice Antigny, Sébastian J. Dumas, Nicolas Raymond, Edmund Lau, Laurent Savale, Xavier Jaïs, Olivier Sitbon, Gérald Simonneau, Kurt Stenmark, Sylvia Cohen-Kaminsky, Marc Humbert, David Montani, Frédéric Perros

Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Session: Pulmonary hypertension: rare and hereditary causes of PAH
Session type: Poster Discussion
Number: 581
Disease area: Pulmonary vascular diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Frederic Perros (le Plessis-Robinson, France), Benoit Ranchoux, Sven Günther, Rozenn Quarck, Marie-Camille Chaumais, Peter Dorfmüller, Fabrice Antigny, Sébastian J. Dumas, Nicolas Raymond, Edmund Lau, Laurent Savale, Xavier Jaïs, Olivier Sitbon, Gérald Simonneau, Kurt Stenmark, Sylvia Cohen-Kaminsky, Marc Humbert, David Montani, Frédéric Perros. Chemotherapy-induced pulmonary hypertension: Role of alkylating agents. Eur Respir J 2015; 46: Suppl. 59, 581

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Mitomycin-induced pulmonary veno-occlusive disease: Experience from the French pulmonary hypertension network
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015


Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014


Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016

Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014

Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014


The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Th17 inflammation and pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Small airways dysfunction in chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Dyspnoea and respiratory muscle mechanics dysfunction in disease
Year: 2015


Female pulmonary arterial hypertension is associated with decreased microRNA96 expression
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Characteristics of patients with pulmonary hypertension in end stage renal disease
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014

Nebivolol and pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

miR-126; link between angiogenesis and exercise intolerance in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014

Smad1 deficiency and female gender contribute to the development of pulmonary hypertension
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014


The evolution of effort tolerance and body composition in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014

Impact of sepsis in respiratory mechanics of pulmonary arterial hypertension rat model. Preliminary results
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014

HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014


Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014